Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Nov 1;6(11):e2343290.
doi: 10.1001/jamanetworkopen.2023.43290.

Mendelian Randomization Analysis of Genetic Proxies of Thiazide Diuretics and the Reduction of Kidney Stone Risk

Jefferson L Triozzi  1 , Ryan S Hsi  2 , Guanchao Wang  3 , Elvis A Akwo  1 , Lee Wheless  4   5 , Hua-Chang Chen  3 , Ran Tao  3   6 , T Alp Ikizler  1 , Cassianne Robinson-Cohen  1 , Adriana M Hung  1   7 ; VA Million Veteran Program
Collaborators, Affiliations
Meta-Analysis

Mendelian Randomization Analysis of Genetic Proxies of Thiazide Diuretics and the Reduction of Kidney Stone Risk

Jefferson L Triozzi et al. JAMA Netw Open. .

Abstract

Importance: Clinical trial data have called into question the efficacy of thiazide diuretics for the prevention of kidney stones.

Objective: To identify whether there is an association between genetic proxies of thiazide diuretics and the risk of kidney stones.

Design, setting, and participants: This genetic association study undertook a mendelian randomization analysis of derived exposures and outcomes from genome-wide association study summary statistics. Genetic proxies of thiazide diuretics were derived from the International Consortium for Blood Pressure. Kidney stone cases and controls were derived from the Million Veteran Program, UK Biobank, and the FinnGen study. These cross-sectional designs do not report a duration of follow-up. Data analysis was performed in May 2023.

Exposure: Genetic proxies of thiazide diuretics were genetic variants in the thiazide-sensitive sodium chloride cotransporter gene associated with systolic blood pressure. Genetic proxies of β-blockers and systolic blood pressure served as negative controls.

Main outcomes and measures: The main outcome was the odds of kidney stones. The secondary outcomes were serum laboratory values relevant to the treatment of kidney stones.

Results: The main analysis included up to 1 079 657 individuals, including 50 832 kidney stone cases and 1 028 825 controls. In a meta-analysis of all cohorts, genetic proxies of thiazide diuretics were associated with a lower odds of kidney stones (OR, 0.85; 95% CI, 0.81-0.89; P < .001). Genetic proxies of β-blockers (OR, 1.02; 95% CI, 0.96-1.07; P = .52) and systolic blood pressure (OR, 1.00; 95% CI, 1.00-1.01; P = .49) were not associated with kidney stones. Genetic proxies of thiazide diuretics were associated with higher serum calcium (β [SE], 0.051 [0.0092]; P < .001) and total cholesterol (β [SE], 0.065 [0.015]; P < .001), but lower serum potassium (β [SE], -0.073 [0.022]; P < .001).

Conclusions and relevance: In this genetic association study, genetic proxies of thiazide diuretics were associated with reduced kidney stone risk. This finding reflects a drug effect over the course of a lifetime, unconstrained by the limited follow-up period of clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hung reported service as cochair of the publication and presentation committee for the Million Veteran Program (MVP) during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Association of Genetic Proxies of Thiazide Diuretics, β-Blockers, and Systolic Blood Pressure With Risk of Kidney Stones
FinnGenn indicates the FinnGen study; MVP, Million Veteran Program; OR, odds ratio; UKB, UK Biobank.
Figure 2.
Figure 2.. Association of Genetic Proxies of Thiazide Diuretics With Serum Laboratory Values
The sizes of boxes indicate the precision of the effect estimate.
See this image and copyright information in PMC

Comment in

References

    1. Hill AJ, Basourakos SP, Lewicki P, et al. . Incidence of kidney stones in the United States: the continuous National Health and Nutrition Examination Survey. J Urol. 2022;207(4):851-856. doi:10.1097/JU.0000000000002331 - DOI - PubMed
    1. Khan SR, Pearle MS, Robertson WG, et al. . Kidney stones. Nat Rev Dis Primers. 2016;2:16008. doi:10.1038/nrdp.2016.8 - DOI - PMC - PubMed
    1. Pearle MS, Goldfarb DS, Assimos DG, et al. ; American Urological Assocation . Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324. doi:10.1016/j.juro.2014.05.006 - DOI - PubMed
    1. Skolarikos A, Straub M, Knoll T, et al. . Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750-763. doi:10.1016/j.eururo.2014.10.029 - DOI - PubMed
    1. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139(4):679-684. doi:10.1016/S0022-5347(17)42599-7 - DOI - PubMed

Publication types

MeSH terms

Substances